Centers of Excellence
Advanced Kidney Cancer
In February, we all waited with bated breath for the results of KEYNOTE-426 and updated results of JAVELIN-101, examining axitinib/pembrolizumab and axitinib/avelumab, respectively.1,2 In the coming months, we will juxtapose these datasets, and compare and contrast with what we know about nivolumab/ipilimumab from CheckMate-214 and cabozantinib from CABOSUN.3,4 These four trials have collectively changed the landscape of what used to be a simple algorithm for metastatic renal cell carcinoma (mRCC).
Sumanta (Monty) Kumar Pal, MD, is an internationally recognized leader in the area of genitourinary cancers, including kidney, bladder, and prostate cancer. He is the Co-director of City of Hope's Kidney Cancer Program and is the head of the kidney and bladder cancer disease. Dr. Pal sits on the Editorial Board for clinical genitourinary cancer and is a reviewer for multiple journals including The Journal of Clinical Oncology, The Journal of Urology, European Urology, and many others.